Gausche M, Persse D E, Sugarman T, Shea S R, Palmer G L, Lewis R J, Brueske P J, Mahadevan S, Melio F R, Kuwate J H
UCLA School of Medicine, Torrance.
Ann Emerg Med. 1994 Aug;24(2):183-9. doi: 10.1016/s0196-0644(94)70128-8.
To determine the efficacy and feasibility of adenosine for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the prehospital setting.
Prospective case series.
Large, urban, advanced life support emergency medical services system.
One hundred twenty-nine adult patients with PSVT, as identified by paramedic personnel. Pregnant patients and those taking carbamazepine or dipyridamole were excluded.
Dose of 12 mg adenosine by rapid i.v. push followed by a 5-mL saline flush and a repeat dose of 12 mg adenosine i.v. push if the patient's rhythm remained unchanged.
Six-second lead II rhythm strips and vital signs were documented before and 2 minutes after the administration of adenosine. Demographic information, past medical history, medications, number of adenosine doses given, and complications were recorded by the paramedic on a case-report form. One hundred six of 129 (82%) of the case-report forms included the rhythm strips from before and after adenosine administration. Actual initial rhythms were determined by a consensus panel. The initial rhythms were PSVT in 79% (84 of 106) of patients, atrial fibrillation in 12% (13 of 106), sinus tachycardia in 5% (five of 106), atrial flutter in 2% (two of 106), and ventricular tachycardia in 2% (two of 106). Eighty-five percent (71 of 84) of patients in PSVT were successfully converted to sinus rhythms; four (5.6%) of these patients required a second 12-mg dose. One patient in atrial fibrillation spontaneously converted to normal sinus rhythm and one patient in ventricular tachycardia converted after adenosine. All other patients not initially in PSVT remained in their initial rhythm. Complications occurred in 12 of 129 patients and included chest pain (five), flushing (three), shortness of breath (two), nausea (one), anxiety (one), dizziness (one), headache (one), and seizure (one). All complications were transient and required no treatment. Prior history of PSVT was the only variable associated with a higher rate of conversion (P = .029).
Paramedics are able to accurately identify PSVT using a single lead. Adenosine is safe and effective treatment for PSVT in the prehospital setting. This series is the largest prehospital study of adenosine use to date.
确定腺苷在院前环境中治疗阵发性室上性心动过速(PSVT)的疗效和可行性。
前瞻性病例系列研究。
大型城市高级生命支持急救医疗服务系统。
经护理人员确诊的129例成年PSVT患者。排除孕妇以及正在服用卡马西平或双嘧达莫的患者。
快速静脉推注12mg腺苷,随后用5ml生理盐水冲管;若患者心律未改变,则重复静脉推注12mg腺苷。
在给予腺苷前及给药后2分钟记录II导联6秒心律条图和生命体征。护理人员在病例报告表上记录人口统计学信息、既往病史、用药情况、腺苷给药剂量及并发症。129份病例报告表中有106份(82%)包含腺苷给药前后的心律条图。实际初始心律由一个共识小组确定。初始心律为PSVT的患者占79%(106例中的84例),房颤占12%(106例中的13例),窦性心动过速占5%(106例中的5例),房扑占2%(106例中的2例),室性心动过速占2%(106例中的2例)。PSVT患者中有85%(84例中的71例)成功转为窦性心律;其中4例(5.6%)患者需要第二次静脉推注12mg腺苷。1例房颤患者自发转为正常窦性心律,1例室性心动过速患者在使用腺苷后转为窦性心律。所有最初非PSVT的患者维持初始心律。129例患者中有12例出现并发症,包括胸痛(5例)、潮红(3例)、呼吸急促(2例)、恶心(1例)、焦虑(1例)、头晕(1例)、头痛(1例)和癫痫发作(1例)。所有并发症均为短暂性,无需治疗。既往PSVT病史是与较高转复率相关的唯一变量(P = 0.029)。
护理人员能够使用单导联准确识别PSVT。腺苷在院前环境中是治疗PSVT的安全有效药物。本系列研究是迄今为止关于腺苷院前应用的最大规模研究。